11 results

  • astagraf xl

    (tacrolimus extended-release capsules)
    Astellas Pharma US, Inc.
    ASTAGRAF XL® is indicated for the prevention of organ rejection in kidney transplant patients, used in conjunction with other immunosuppressants for both adults and pediatric patients who can swallow capsules intact.

  • cresemba

    (isavuconazonium sulfate)
    Astellas Pharma US, Inc.
    CRESEMBA is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adults and pediatric patients. It is available as an injection for patients aged 1 year and older, and as capsules for those aged 6 years and older who weigh at least 16 kg.

  • izervay

    (avacincaptad pegol)
    Astellas Pharma US, Inc.
    IZERVAY™ is indicated for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD).

  • lexiscan

    (regadenoson)
    Astellas Pharma US, Inc.
    LEXISCAN® (regadenoson) injection is indicated as a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients who cannot perform adequate exercise stress.

  • mycamine

    (Micafungin sodium)
    Astellas Pharma US, Inc.
    MYCAMINE® is indicated for treating candidemia, acute disseminated candidiasis, Candida peritonitis, and esophageal candidiasis in patients 4 months and older. It is also used for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Use in pediatric patients under 4 months has limitations.

  • myrbetriq

    (mirabegron)
    Astellas Pharma US, Inc.
    MYRBETRIQ is indicated for treating adult overactive bladder (OAB) symptoms, including urge urinary incontinence, urgency, and urinary frequency, either alone or with solifenacin succinate. It is also indicated for pediatric patients (ages 3+) with neurogenic detrusor overactivity (NDO) who weigh 35 kg or more.

  • prograf

    (Tacrolimus)
    Astellas Pharma US, Inc.
    PROGRAF® is indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic transplants of the kidney, liver, heart, or lung, as part of a regimen with other immunosuppressants.

  • veozah

    (fezolinetant)
    Astellas Pharma US, Inc.
    VEOZAH® is indicated for treating moderate to severe vasomotor symptoms associated with menopause.

  • vyloy

    (ZOLBETUXIMAB)
    Astellas Pharma US, Inc.
    VYLOY is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, specifically for those with claudin 18.2 positive tumors, in combination with fluoropyrimidine- and platinum-containing chemotherapy.

  • xospata

    (gilteritinib)
    Astellas Pharma US, Inc.
    XOSPATA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation, confirmed by an FDA-approved test.